ORGS logo

Orgenesis (ORGS) Company Overview

Profile

Full Name:

Orgenesis Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

March 13, 2012

Indexes:

Not included

Description:

Orgenesis is a biotechnology company focused on developing and commercializing cell and gene therapies. They aim to transform how diseases are treated by using innovative technologies to produce personalized medicine, improving patient outcomes and making advanced therapies more accessible.

Key Details

Price

$1.18

Annual Revenue

$530.00 K(-98.53% YoY)

Annual EPS

-$19.10(-223.73% YoY)

Annual ROE

-289.16%

Beta

0.94

Events Calendar

Earnings

Next earnings date:

May 21, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

Mar 21, 2023
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Sep 25, 2024

Analyst ratings

Recent major analysts updates

Jun 14, 23 Benchmark
Speculative Buy
Mar 22, 23 Benchmark
Buy
Sep 26, 19 Benchmark
Speculative Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings
Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings
Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings
ORGS
accessnewswire.comJanuary 28, 2025

Funding Aimed at Accelerating Rollout of Decentralized CGT Platform GERMANTOWN, MD / ACCESS Newswire / January 28, 2025 / Orgenesis Inc . (OTCQX:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today announced that it has concluded an agreement for an equity line of credit of up to $5 million from Williamsburg Venture Holdings, LLC, a Nevada-based family office.

Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia
Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia
Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia
ORGS
globenewswire.comAugust 29, 2024

Orgenesis' CD19 CAR-T therapy, ORG-101, had a complete  response (CR) of 82% in adults and 93% in pediatric patients with the incidence of severe Cytokine Release Syndrome (CRS) of 2% in adult patients and 6% in pediatric patients in a real-world study

Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally
Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally
Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally
ORGS
globenewswire.comAugust 14, 2024

The strategic alliance aims to drive new-age innovation in wellness & longevity, backed by an investment commitment of up to $10 million over 3 years into both Orgenesis and the newly formed joint venture The strategic alliance aims to drive new-age innovation in wellness & longevity, backed by an investment commitment of up to $10 million over 3 years into both Orgenesis and the newly formed joint venture

FAQ

  • What is the ticker symbol for Orgenesis?
  • Does Orgenesis pay dividends?
  • What sector is Orgenesis in?
  • What industry is Orgenesis in?
  • What country is Orgenesis based in?
  • When did Orgenesis go public?
  • Is Orgenesis in the S&P 500?
  • Is Orgenesis in the NASDAQ 100?
  • Is Orgenesis in the Dow Jones?
  • When was Orgenesis's last earnings report?
  • When does Orgenesis report earnings?
  • Should I buy Orgenesis stock now?

What is the ticker symbol for Orgenesis?

The ticker symbol for Orgenesis is NASDAQ:ORGS

Does Orgenesis pay dividends?

No, Orgenesis does not pay dividends

What sector is Orgenesis in?

Orgenesis is in the Healthcare sector

What industry is Orgenesis in?

Orgenesis is in the Biotechnology industry

What country is Orgenesis based in?

Orgenesis is headquartered in United States

When did Orgenesis go public?

Orgenesis's initial public offering (IPO) was on March 13, 2012

Is Orgenesis in the S&P 500?

No, Orgenesis is not included in the S&P 500 index

Is Orgenesis in the NASDAQ 100?

No, Orgenesis is not included in the NASDAQ 100 index

Is Orgenesis in the Dow Jones?

No, Orgenesis is not included in the Dow Jones index

When was Orgenesis's last earnings report?

Orgenesis's most recent earnings report was on Nov 13, 2024

When does Orgenesis report earnings?

The next expected earnings date for Orgenesis is May 21, 2025

Should I buy Orgenesis stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions